ArticleOpen forum infectious diseases2015
Molecular Detection and Characterization of Mycoplasma pneumoniae Among Patients Hospitalized With Community-Acquired Pneumonia in the United States.
Article in Open forum infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Global molecular epidemiology ofEmerging microbes & infections · 2026Pooled it
- Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis.JAMA network open · 2022Pooled it
- Trial
- Article
- Clinical characteristics of mycoplasma pneumoniae pneumonia in children with 23 S rRNA mutations in domain V and exploration of the timing of glucocorticoid therapy.BMC infectious diseases · 2025Article
- Article
- D-dimer serves as predictor of plastic bronchitis or necrotizing pneumonia in children withFrontiers in pediatrics · 2025Article
- Comparative observation between Roxithromycin and Azithromycin sequential therapy in the treatment of Mycoplasma pneumoniae Pneumonia in Children.Pakistan journal of medical sciences · 2024Article
- Clinical and Epidemiologic Features ofInternational journal of medical sciences · 2024Article
- The molecular characteristics, diagnosis, and treatment of macrolide-resistantFrontiers in pediatrics · 2023Review
- Antimicrobial Susceptibility Profiles and Genetic Characteristics ofInfection and drug resistance · 2022Article
- Macrolide Resistance, Clinical Features, and Cytokine Profiles in Taiwanese Children WithOpen forum infectious diseases · 2021Article
- Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA.Emerging infectious diseases · 2021Article
- Article
- Early diagnosis and appropriate respiratory support for Mycoplasma pneumoniae pneumonia associated acute respiratory distress syndrome in young and adult patients: a case series from two centers.BMC infectious diseases · 2020Observational
- Etiology of community-acquired pneumonia in adults: a systematic review.Pneumonia (Nathan Qld.) · 2020Review
- Comparing Antimicrobial Susceptibilities amongAntimicrobial agents and chemotherapy · 2019Article
- Mycoplasma pneumoniae Among Children Hospitalized With Community-acquired Pneumonia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- First Description of Macrolide-ResistantBioMed research international · 2019Article
- Detection ofInfection and drug resistance · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 1 country.
Funding
Abstract
Background. Mycoplasma pneumoniae is a common cause of community-acquired pneumonia (CAP). The molecular characteristics of M pneumoniae detected in patients hospitalized with CAP in the United States are poorly described. Methods. We performed molecular characterization of M pneumoniae in nasopharyngeal/oropharyngeal swabs from children and adults hospitalized with CAP in the Centers for Disease Control and Prevention Etiology of Pneumonia in the Community (EPIC) study, including P1 typing, multilocus variable-number tandem-repeat analysis (MLVA), and macrolide susceptibility genotyping. Results. Of 216 M pneumoniae polymerase chain reaction-positive specimens, 40 (18.5%) were obtained from adults and 176 (81.5%) from children. P1 type distribution differed between adults (64% type 1 and 36% type 2) and children (84% type 1, 13% type 2, and 3% variant) (P < .05) and among sites (P < .01). Significant differences in the proportions of MLVA types 4/5/7/2 and 3/5/6/2 were also observed by age group (P < .01) and site (P < .01). A macrolide-resistant genotype was identified in 7 (3.5%) specimens, 5 of which were from patients who had recently received macrolide therapy. No significant differences in clinical characteristics were identified among patients with various strain types or between macrolide-resistant and -sensitive M pneumoniae infections. Conclusions. The P1 type 1 genotype and MLVA type 4/5/7/2 predominated, but there were differences between children and adults and among sites. Macrolide resistance was rare. Differences in strain types did not appear to be associated with differences in clinical outcomes. Whole genome sequencing of M pneumoniae may help identify better ways to characterize strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.